Buscar
Arvinas Inc
ARVNAñadir a la lista de seguimiento
8.440USD
-0.010-0.12%
Horarios del mercado 09/14, 15:22（ET）
551.13MCap. mercado
PérdidaP/E TTM
Más Datos de Arvinas Inc Compañía
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Perfil de Arvinas Inc
Símbolo de cotizaciónARVN
Nombre de la empresaArvinas Inc
Fecha de salida a bolsaSep 27, 2018
Director ejecutivoDr. John G. Houston, Ph.D.
Número de empleados430
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 27
Dirección5 Science Park
CiudadNEW HAVEN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal06511-1966
Teléfono12035351456
Sitio Webhttps://www.arvinas.com/
Símbolo de cotizaciónARVN
Fecha de salida a bolsaSep 27, 2018
Director ejecutivoDr. John G. Houston, Ph.D.
Ejecutivos de Arvinas Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Director
Director
992.69K
+11.66%
Dr. Randy Teel, Ph.D.
Dr. Randy Teel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
69.86K
-16.99%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
25.55K
+60.78%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
25.55K
+60.78%
Mr. Edward (Ted) Kennedy, Jr.
Mr. Edward (Ted) Kennedy, Jr.
Independent Director
Independent Director
--
--
Dr. Briggs W. Morrison, M.D.
Dr. Briggs W. Morrison, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
Ms. Linda C. Bain
Ms. Linda C. Bain
Independent Director
Independent Director
--
--
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Chief Financial Officer, Treasurer, Principal Financial Officer
Chief Financial Officer, Treasurer, Principal Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Director
Director
992.69K
+11.66%
Dr. Randy Teel, Ph.D.
Dr. Randy Teel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
69.86K
-16.99%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
25.55K
+60.78%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
25.55K
+60.78%
Mr. Edward (Ted) Kennedy, Jr.
Mr. Edward (Ted) Kennedy, Jr.
Independent Director
Independent Director
--
--
Dr. Briggs W. Morrison, M.D.
Dr. Briggs W. Morrison, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Arvinas Inc?
Los cinco principales accionistas de Arvinas Inc son: Dr. John G. Houston, Ph.D.
¿Cuántas instituciones poseen acciones de Arvinas Inc (ARVN)?
A fecha de 2026Q1, 522 instituciones poseen acciones de Arvinas Inc, con un valor de mercado combinado de aproximadamente 53.93M, lo que representa el 83.59% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -45351418.00.